专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US08598356B2 Heteroaryl-substituted urea modulators of fatty acid amide hydrolase 有权
公开(公告)号：US08598356B2
公开(公告)日：2013-12-03
申请号：US13131061
申请日：2009-11-24
申请人： J. Guy Breitenbucher , John M. Keith , Mark S. Tichenor , Alison L. Chambers , William M. Jones , Natalie A. Hawryluk , Amy K. Timmons , Jeffrey E. Merit , Mark J. Seierstad
发明人： J. Guy Breitenbucher , John M. Keith , Mark S. Tichenor , Alison L. Chambers , William M. Jones , Natalie A. Hawryluk , Amy K. Timmons , Jeffrey E. Merit , Mark J. Seierstad
IPC分类号： C07D211/68 , A61K31/445
CPC分类号： C07D498/04 , A61K31/437 , A61K31/454 , A61K31/4545 , A61K31/4709 , A61K31/5025 , A61K31/506 , A61K45/06 , C07D401/12 , C07D401/14 , C07D405/14 , C07D413/12 , C07D471/04 , C07D487/04
摘要： Certain heteroaryl-substituted piperidinyl and piperazinyl urea compounds are described, which are useful as FAAH inhibitors. Such compounds may be used in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by fatty acid amide hydrolase (FAAH) activity, such as anxiety, pain, inflammation, sleep disorders, eating disorders, insulin resistance, diabetes, osteoporosis, and movement disorders (e.g., multiple sclerosis).

2. 发明授权

US08901111B2 Aryl-substituted heterocyclic urea modulators of fatty acid amide hydrolase 有权
标题翻译：脂肪酰胺水解酶的芳基取代的杂环脲调节剂
公开(公告)号：US08901111B2
公开(公告)日：2014-12-02
申请号：US13375855
申请日：2010-06-04
申请人： J. Guy Breitenbucher , Mark S. Tichenor , Jeffrey E. Merit , Natalie A. Hawryluk , Alison L. Chambers , John M. Keith
发明人： J. Guy Breitenbucher , Mark S. Tichenor , Jeffrey E. Merit , Natalie A. Hawryluk , Alison L. Chambers , John M. Keith
IPC分类号： A61K31/616 , C07D401/12 , C07D405/14 , C07D401/14 , C07D471/04 , A61K31/5025 , A61K31/4427 , A61K31/443 , A61K31/4709 , A61K31/4725 , A61K31/4439 , A61K31/437 , C12N9/99 , A61P25/04 , A61P29/00 , A61P25/22 , A61P25/24 , A61P25/00 , A61P25/14 , A61P25/28 , A61P25/08 , A61P25/16 , A61P1/08 , A61P15/00 , A61P27/06 , A61P1/00 , A61P1/04 , A61P1/12 , A61P19/02 , A61P9/12 , A61P35/00 , A61P3/10 , A61P17/04 , A61P19/10 , A61P3/00 , C07D487/04 , C07D413/12
CPC分类号： C07D487/04 , C07D401/12 , C07D401/14 , C07D413/12 , C07D471/04
摘要： Certain aryl-substituted heterocyclic urea compounds are described, which are useful as FAAH inhibitors. Such compounds may be used in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by fatty acid amide hydrolase (FAAH) activity, such as anxiety, pain, inflammation, sleep disorders, eating disorders, energy metabolism disorders, and movement disorders (e.g., multiple sclerosis).
摘要翻译：描述了某些芳基取代的杂环脲化合物，其可用作FAAH抑制剂。这些化合物可用于治疗由脂肪酰胺水解酶（FAAH）活性介导的疾病状态，病症和病症的药物组合物和方法，例如焦虑症，疼痛，炎症，睡眠障碍，进食障碍，能量代谢紊乱，和运动障碍（例如多发性硬化）。

3. 发明授权

US08461159B2 Heteroaryl-substituted urea modulators of fatty acid amide hydrolase 有权
标题翻译：脂肪酰胺水解酶的杂芳基取代的脲调节剂
公开(公告)号：US08461159B2
公开(公告)日：2013-06-11
申请号：US13131067
申请日：2009-11-24
申请人： J. Guy Breitenbucher , John M. Keith , Mark S. Tichenor , Alison L. Chambers , William M. Jones , Natalie A. Hawryluk , Amy K. Timmons , Jeffrey E. Merit , Mark J. Seierstad
发明人： J. Guy Breitenbucher , John M. Keith , Mark S. Tichenor , Alison L. Chambers , William M. Jones , Natalie A. Hawryluk , Amy K. Timmons , Jeffrey E. Merit , Mark J. Seierstad
IPC分类号： A61K31/495 , C07D419/00
CPC分类号： C07D498/04 , C07D231/56 , C07D295/195 , C07D403/12 , C07D413/12 , C07D413/14 , C07D471/04 , C07D471/12 , C07D487/04
摘要： Certain heteroaryl-substituted piperidinyl and piperazinyl urea compounds are described, which are useful as FAAH inhibitors. Such compounds may be used in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by fatty acid amide hydrolase (FAAH) activity, such as anxiety, pain, inflammation, sleep disorders, eating disorders, insulin resistance, diabetes, osteoporosis, and movement disorders (e.g., multiple sclerosis).
摘要翻译：描述了某些杂芳基取代的哌啶基和哌嗪基脲化合物，其可用作FAAH抑制剂。这些化合物可用于治疗由脂肪酸酰胺水解酶（FAAH）活性介导的疾病状态，病症和病症的药物组合物和方法，例如焦虑症，疼痛，炎症，睡眠障碍，进食障碍，胰岛素抵抗，糖尿病，骨质疏松症和运动障碍（例如，多发性硬化症）。

4. 发明申请

US20110237596A1 HETEROARYL-SUBSTITUTED UREA MODULATORS OF FATTY ACID AMIDE HYDROLASE 有权
标题翻译：脂肪酸酰胺水解物的替代尿素调节剂
公开(公告)号：US20110237596A1
公开(公告)日：2011-09-29
申请号：US13131067
申请日：2009-11-24
申请人： J. Guy Breitenbucher , John M. Keith , Mark S. Tichenor , Alison L. Chambers , William M. Jones , Natalie A. Hawryluk , Amy K. Timmons , Jeffrey E. Merit , Mark J. Seierstad
发明人： J. Guy Breitenbucher , John M. Keith , Mark S. Tichenor , Alison L. Chambers , William M. Jones , Natalie A. Hawryluk , Amy K. Timmons , Jeffrey E. Merit , Mark J. Seierstad
IPC分类号： A61K31/5025 , C07D413/14 , A61K31/497 , A61K31/4709 , A61P25/24 , C07D471/04 , A61K31/4353 , C07D487/04 , A61P25/22 , A61P29/00 , A61P3/00 , A61P31/18 , A61K31/501 , A61P25/00 , A61P25/28 , A61P25/16 , A61P25/30 , A61P27/02 , A61P37/00 , A61P15/00 , A61P1/00 , A61P1/12 , A61P1/04 , A61P19/02 , A61P9/12 , A61P35/00 , A61P37/08 , A61P3/10
CPC分类号： C07D498/04 , C07D231/56 , C07D295/195 , C07D403/12 , C07D413/12 , C07D413/14 , C07D471/04 , C07D471/12 , C07D487/04
摘要： Certain heteroaryl-substituted piperidinyl and piperazinyl urea compounds are described, which are useful as FAAH inhibitors. Such compounds may be used in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by fatty acid amide hydrolase (FAAH) activity, such as anxiety, pain, inflammation, sleep disorders, eating disorders, insulin resistance, diabetes, osteoporosis, and movement disorders (e.g., multiple sclerosis).
摘要翻译：描述了某些杂芳基取代的哌啶基和哌嗪基脲化合物，其可用作FAAH抑制剂。这些化合物可用于治疗由脂肪酸酰胺水解酶（FAAH）活性介导的疾病状态，病症和病症的药物组合物和方法，例如焦虑症，疼痛，炎症，睡眠障碍，进食障碍，胰岛素抵抗，糖尿病，骨质疏松症和运动障碍（例如，多发性硬化症）。

5. 发明申请

US20110230490A1 HETEROARYL-SUBSTITUTED UREA MODULATORS OF FATTY ACID AMIDE HYDROLASE 有权
公开(公告)号：US20110230490A1
公开(公告)日：2011-09-22
申请号：US13131061
申请日：2009-11-24
申请人： J. Guy Breitenbucher , John M. Keith , Mark S. Tichenor , Alison L. Chambers , William M. Jones , Natalie A. Hawryluk , Amy K Timmons , Jeffrey E. Merit , Mark J. Seierstad
发明人： J. Guy Breitenbucher , John M. Keith , Mark S. Tichenor , Alison L. Chambers , William M. Jones , Natalie A. Hawryluk , Amy K Timmons , Jeffrey E. Merit , Mark J. Seierstad
IPC分类号： A61K31/5025 , C07D405/14 , A61K31/4545 , A61P29/00 , A61P25/04 , A61P25/22 , A61P25/24 , A61P9/10 , A61P25/08 , A61P25/30 , A61P1/08 , A61P15/00 , A61P37/06 , A61P19/02 , C07D401/12 , A61K31/506 , C07D413/12 , A61K31/454 , C07D487/04 , A61K31/4709 , C07D401/14 , C07D471/04 , A61K31/437
CPC分类号： C07D498/04 , A61K31/437 , A61K31/454 , A61K31/4545 , A61K31/4709 , A61K31/5025 , A61K31/506 , A61K45/06 , C07D401/12 , C07D401/14 , C07D405/14 , C07D413/12 , C07D471/04 , C07D487/04
摘要： Certain heteroaryl-substituted piperidinyl and piperazinyl urea compounds are described, which are useful as FAAH inhibitors. Such compounds may be used in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by fatty acid amide hydrolase (FAAH) activity, such as anxiety, pain, inflammation, sleep disorders, eating disorders, insulin resistance, diabetes, osteoporosis, and movement disorders (e.g., multiple sclerosis).

6. 发明申请

US20090062294A1 HETEROARYL-SUBSTITUTED UREA MODULATORS OF FATTY ACID AMIDE HYDROLASE 审中-公开
标题翻译：脂肪酸酰胺水解物的替代尿素调节剂
公开(公告)号：US20090062294A1
公开(公告)日：2009-03-05
申请号：US12126389
申请日：2008-05-23
申请人： Richard Apodaca , J. Guy Breitenbucher , Natalie A. Hawryluk , William M. Jones , John M. Keith , Jeffrey E. Merit , Mark S. Tichenor , Amy K. Timmons
发明人： Richard Apodaca , J. Guy Breitenbucher , Natalie A. Hawryluk , William M. Jones , John M. Keith , Jeffrey E. Merit , Mark S. Tichenor , Amy K. Timmons
IPC分类号： A61K31/501 , C07D401/00 , C07D403/00 , C07D403/14 , A61P35/00 , A61P25/00 , A61P1/04 , A61P9/00 , A61P37/00 , A61P31/12 , A61P1/00 , A61K31/445 , A61K31/496
CPC分类号： C07D231/40 , C07D237/20 , C07D241/20 , C07D257/06 , C07D261/14 , C07D261/20 , C07D271/12 , C07D285/14 , C07D401/12 , C07D403/12 , C07D405/12 , C07D409/12 , C07D413/12 , C07D413/14 , C07D417/12 , C07D471/04
摘要： Certain heteroaryl-substituted piperidinyl and piperazinyl urea compounds are described, which are useful as FAAH inhibitors. Such compounds may be used in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by fatty acid amide hydrolase (FAAH) activity, such as anxiety, pain, inflammation, sleep disorders, eating disorders, insulin resistance, diabetes, osteoporosis, and movement disorders (e.g., multiple sclerosis).
摘要翻译：描述了某些杂芳基取代的哌啶基和哌嗪基脲化合物，其可用作FAAH抑制剂。这些化合物可用于治疗由脂肪酸酰胺水解酶（FAAH）活性介导的疾病状态，病症和病症的药物组合物和方法，例如焦虑症，疼痛，炎症，睡眠障碍，进食障碍，胰岛素抵抗，糖尿病，骨质疏松症和运动障碍（例如，多发性硬化症）。

7. 发明申请

US20120088741A1 ARYL-SUBSTITUTED HETEROCYCLIC UREA MODULATORS OF FATTY ACID AMIDE HYDROLASE 有权
标题翻译：脂肪酸酰胺水解酶的ARYL取代的杂环尿素调节剂
公开(公告)号：US20120088741A1
公开(公告)日：2012-04-12
申请号：US13375855
申请日：2010-06-04
申请人： J. Guy Breitenbucher , Mark S. Tichenor , Jeffrey E. Merit , John M. Keith , Natallie A. Hawryluk , Alison L. Chambers
发明人： J. Guy Breitenbucher , Mark S. Tichenor , Jeffrey E. Merit , John M. Keith , Natallie A. Hawryluk , Alison L. Chambers
IPC分类号： A61K31/616 , C07D401/12 , C07D405/14 , C07D401/14 , C07D471/04 , A61K31/5025 , A61K31/4427 , A61K31/443 , A61K31/4709 , A61K31/4725 , A61K31/4439 , A61K31/437 , C12N9/99 , A61P25/04 , A61P29/00 , A61P25/22 , A61P25/24 , A61P25/00 , A61P25/14 , A61P25/28 , A61P25/08 , A61P25/16 , A61P1/08 , A61P15/00 , A61P27/06 , A61P1/00 , A61P1/04 , A61P1/12 , A61P19/02 , A61P9/12 , A61P35/00 , A61P3/10 , A61P17/04 , A61P19/10 , A61P3/00 , C07D487/04
CPC分类号： C07D487/04 , C07D401/12 , C07D401/14 , C07D413/12 , C07D471/04
摘要： Certain aryl-substituted heterocyclic urea compounds are described, which are useful as FAAH inhibitors. Such compounds may be used in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by fatty acid amide hydrolase (FAAH) activity, such as anxiety, pain, inflammation, sleep disorders, eating disorders, energy metabolism disorders, and movement disorders (e.g., multiple sclerosis).
摘要翻译：描述了某些芳基取代的杂环脲化合物，其可用作FAAH抑制剂。这些化合物可用于治疗由脂肪酰胺水解酶（FAAH）活性介导的疾病状态，病症和病症的药物组合物和方法，例如焦虑症，疼痛，炎症，睡眠障碍，进食障碍，能量代谢紊乱，和运动障碍（例如多发性硬化）。

8. 发明授权

US07618524B1 Polymeric salt bridges for conducting electric current in microfluidic devices 有权
标题翻译：用于在微流体装置中传导电流的聚合盐桥
公开(公告)号：US07618524B1
公开(公告)日：2009-11-17
申请号：US10916310
申请日：2004-08-10
申请人： Timothy J. Shepodd , Mark S. Tichenor , Alexander Artau
发明人： Timothy J. Shepodd , Mark S. Tichenor , Alexander Artau
IPC分类号： G01N27/453
CPC分类号： F04B19/006 , B01L3/502707 , B01L3/502738 , B01L2200/143 , B01L2300/0816 , B01L2400/0418 , B01L2400/0421
摘要： A “cast-in-place” monolithic microporous polymer salt bridge for conducting electrical current in microfluidic devices, and methods for manufacture thereof is disclosed. Polymeric salt bridges are formed in place in capillaries or microchannels. Formulations are prepared with monomer, suitable cross-linkers, solvent, and a thermal or radiation responsive initiator. The formulation is placed in a desired location and then suitable radiation such as UV light is used to polymerize the salt bridge within a desired structural location. Embodiments are provided wherein the polymeric salt bridges have sufficient porosity to allow ionic migration without bulk flow of solvents therethrough. The salt bridges form barriers that seal against fluid pressures in excess of 5000 pounds per square inch. The salt bridges can be formulated for carriage of suitable amperage at a desired voltage, and thus microfluidic devices using such salt bridges can be specifically constructed to meet selected analytical requirements.
摘要翻译：公开了一种用于在微流体装置中传导电流的“现浇”整体式微孔聚合物盐桥及其制造方法。在毛细管或微通道中形成聚合盐桥。制剂用单体，合适的交联剂，溶剂和热或辐射响应性引发剂制备。将配方放置在所需的位置，然后使用合适的辐射（例如UV光）使盐桥在期望的结构位置聚合。提供了实施例，其中聚合物盐桥具有足够的孔隙度以允许离子迁移，而不会使溶剂流过其中。盐桥形成了密封超过5000磅/平方英寸的流体压力的障碍物。盐桥可以配制成以所需的电压运送合适的电流，因此使用这种盐桥的微流体装置可以被特别地构造以满足所选择的分析要求。

9. 发明申请

US20160039790A1 1,2,6-SUBSTITUTED BENZIMIDAZOLES AS FLAP MODULATORS 有权
公开(公告)号：US20160039790A1
公开(公告)日：2016-02-11
申请号：US14777492
申请日：2014-03-13
申请人： Wenying CHAI , Curt A. DVORAK , Wendy ECCLES , James P. EDWARDS , Steven D. GOLDBERG , Paul J. KRAWCZUK , Alec D. LEBSACK , Jing LIU , Daniel J. PIPPEL , Zachary S. SALES , Virginia M. TANIS , Mark S. TICHENOR , John J.M. WIENER , JANSSEN PHARMACEUTICA NV
发明人： Wenying Chai , Curt A. Dvorak , Wendy Eccles , James P. Edwards , Steven D. Goldberg , Paul J. Krawczuk , Alec D. Lebsack , Jing Liu , Daniel J. Pippel , Zachary S. Sales , Virginia M. Tanis , Mark S. Tichenor , John J. M. Wiener
IPC分类号： C07D401/12 , C07D401/14 , C07D403/14 , C07D403/12
CPC分类号： C07D401/12 , A61K31/4184 , A61K31/4439 , A61K31/454 , A61K31/4545 , A61K31/506 , C07D401/14 , C07D403/12 , C07D403/14
摘要： The present invention relates to compounds of Formula (I), and solvates, hydrates, and pharmaceutically acceptable salts thereof, wherein X1, X1′, X1″, R1, R2 and R3 are as defined herein, useful as FLAP modulators. The invention also relates to pharmaceutical compositions comprising compounds of Formula (I). Methods of making and using the compounds of Formula (I) are also within the scope of the invention.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式